Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients

Gut

Volumn 52, Issue 7, 2003, Pages 1035-1040

  Mohsen, A H ^a   Easterbrook, P J ^a   Taylor, C ^a   Portmann, B ^b   Kulasegaram, R ^c   Murad, S ^a   Wiselka, M ^d   Norris, S ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RNA ANALYSIS; SCORING SYSTEM; UNITED KINGDOM;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTIGENS, CD4; BIOPSY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; RNA, VIRAL; SEX FACTORS; TIME FACTORS;

EID: 0038798716     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.7.1035     Document Type: Article

References (49)

1. Mohsen A, Easterbrook P, Taylor C, et al. Hepatitis C and HIV-1 infection. Gut 2002;4:601-8.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
4. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
5. Puoti M, Spinetti A, Ghezzi A, et al. Mortality from liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-17.
6. Martín-Carbonero L, Soriano V, Valencia ME, et al. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-71.
7. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis 2001;32:1207-14.
8. Darby SC, Ewart DW Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-31.
9. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993;6:602-10.
10. Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-52.
11. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-8.
12. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
13. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19.
14. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
16. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
18. Siegl S. Non-Parametric Statistic for Behavioral Sciences. New York: McGraw-Hill, 1956.
19. Stata Reference Manual (release 7). Texas: Stata Corporation, 2000.
20. Arizcorreta C, Martinez C, Diaz F, et al. Liver Fibrosis and Cirrhosis in Human Immunodeficiency Virus Co-infected Patients. 14th World AIDS Conference, 6-12 July 2002, Barcelona, Spain (abstract B6036).
21. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-7.
22. Fuster D, Tural C, Romeu J, et al. Factors Associated with Liver Fibrosis in HIV-1 HCV Coinfected on Antiretroviral Therapy. 9th Conference on Retrovirosis and Opportunistic Infection, 10-14 February 2002, Chicago, USA (abstract 646-M).
23. Gane EJ, Portmann BC, Naoumoy NV, et al. Long-term outcome of chronic hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
24. Bjorkander J, Cunningham-Rudles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or llgG subclass deficiency. Am J Med 1988;84:107-11.
25. Eyster ME, Fried MW, Di Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to HIV infection and liver disease. Blood 1994;84:1020-3.
26. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
27. Beld M, Penning M, Lukashov V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998;244:504-12.
28. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alfa for the treatment of chronic hepatitis C in patients with HIV. Clin Infect Dis 1996;23:585-91.
29. Healey CJ, Chapman RW, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut. 1995;37:274-8.
30. Rai R, Wilson LE, Astemborski J, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepotology 2002;35:1247-55.
31. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
32. Shindo M, Arai K, Sokawa Y, et al. The virological and histological states of anti- hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418-25.
33. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistenty normal alanine aminotransferase levels. Gut 2002;51:585-90.
34. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-7
35. Kouvatsos P, Doerfler RE, Woodward WC. ALT Does Not Predict Hepatic Fibrosis in HIV/HCV Co-infected Patients on Antiretroviral Therapy. 14th World AIDS Conference, 6-12 July 2002, Barcelona, Spain (abstract WePeB6040).
36. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-41.
37. Mangia A, Cascavilla I, Lezzi G, et al. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 1997;26:1173-8.
38. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;5:707-13.
39. Garcio-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotype and HIV infection on histological severity of chronc hepatitis C. The Hepatitis/HIV Study Group. Am J Gastroenterol 1997;92:1130-4.
40. Gordon SC, Bayati N, Silverman AL. Clinical outcome of HCV as a function of mode of transmission. Hepatology 1998;28:562-7.
41. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-7.
42. Losada-Arias E, Prieto-Martinez A, Villamil-Cajoto I, et al. Liver Damage in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients: Relationship with Immunological Status. 14th World AIDS Conference, 6-12 July 2002, Barcelona, Spain (abstract ThPeC7508).
43. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
44. Yamada M, Kakuma S, Yoshioka K, et al. Hepatitis C virus genotypes are not responsible for development of liver disease. Dig Dis Sci 1994;39:234-9.
45. Mita E, Hayashi N, Kanazawa Y, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994;21:468-73
46. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. 1994. Hepatitis C virus genotypes: an investigation of type-specific differences in geo-graphic origin and disease. Hepatology 1994;19:13-18.
47. Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hematology 1997;25:211-15.
48. Yee TT, Griffioen A, Sabin CA; et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000;47:845-51.
49. Noone A, Durante AJ, Brady AR, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. J Acquir Immune Defic Syndr 1993;7:1501-7.